Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376916 · ClinicalTrials.gov registry record · Phase 3
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
A Phase 3 study of Atrial Fibrillation and Tachycardia Atrial, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 153
- Enrollment target
- 1
- Study location
NCT06376916: Recruiting Phase 3 study of Atrial Fibrillation and Tachycardia Atrial, sponsored by Wake Forest University Health Sciences.
NCT06376916 is a Phase 3 study of Atrial Fibrillation and Tachycardia Atrial that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 153 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376916, a Phase 3 study of Atrial Fibrillation and Tachycardia Atrial, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 153 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Primary Outcome
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of \< 120 bpm.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Magnesium Sulfate 2 G
- DRUG Magnesium Sulfate 4 G
Study Locations (1)
Illinois
- Advocate Christ Medical Center Emergency Department (ACMC ED) - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
What NCT06376916 shows while recruiting
NCT06376916 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT06376916 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06376916 about?
NCT06376916 is a clinical study titled "Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR". The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
What is the current status of trial NCT06376916?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2024-10-07. Estimated completion is 2026-12.
What conditions does trial NCT06376916 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Tachycardia Atrial, Atrial Flutter With Rapid Ventricular Response.
What interventions are being tested in trial NCT06376916?
The interventions under investigation include: Saline (DRUG), Magnesium Sulfate 2 G (DRUG), Magnesium Sulfate 4 G (DRUG).
Who is sponsoring clinical trial NCT06376916?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376916 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06376916's enrollment target sits among peer trials
153 118th of 202 higher than 85 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI